Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Small Lymphocytic LymphomaAnn Arbor Stage III Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage IV Marginal Zone LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Indolent Adult Non-Hodgkin LymphomaAnn Arbor Stage IV Small Lymphocytic Lymphoma
- Interventions
- Biological: Rituximab
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 156
- Registration Number
- NCT00695786
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Sequential Maintenance Therapy
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Cristina Gasparetto
- Target Recruit Count
- 18
- Registration Number
- NCT00691704
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1623
- Registration Number
- NCT00689936
- Locations
- 🇺🇸
Cedar Sinai Medical Center Dept of Medicine, Los Angeles, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT00687674
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00684242
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00679367
- Locations
- 🇺🇸
Boston University Cancer Research Center, Boston, Massachusetts, United States
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00675441
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00671801
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 138
- Registration Number
- NCT00670358
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
- Conditions
- Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)Neuropathy
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT00665652
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.